About this trial
The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty.
Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale \[NRS\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."
Eligibility criteria
Qualifiers
Adults aged >18 years of age
ASA I-III
Scheduled for elective ambulatory total shoulder arthroplasty.
Disqualifiers
ASA IV
Revision surgery
Contraindication to regional anesthesia (such as allergy to local anesthetics, systemic anticoagulation, local infection)
Preoperative chronic pain or opioid use
Trial design
Treatments tested in this trial
- Continuous interscalene nerve block
- Interscalene Block